Entera Bio Ltd. (ENTX) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Entera Bio Ltd. is a clinical-stage biopharmaceutical company developing first-in-class oral tablet formats of peptides or protein replacement therapies using its proprietary N-Tab™ technology. The company's primary focus is on underserved chronic conditions, specifically osteoporosis (EB613), hypoparathyroidism (EB612), and metabolic disorders (Oral OXM/GLP-1 in collaboration with OPKO).
Key Financial Metrics
| Metric (in thousands USD) | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenues | $42 | $0 |
| Net Loss | $(2,567) | $(2,017) |
| Operating Loss | $(2,563) | $(2,062) |
| Research & Development Expenses | $1,123 | $735 |
| General & Administrative Expenses | $1,440 | $1,327 |
| Cash and Cash Equivalents | $12,573 | $9,189 |
| Restricted Cash | $8,000 | $0 |
| Total Cash & Restricted Cash | $20,665 | $9,253 |
| Accumulated Deficit | $(116,494) | $(106,403) |
| Shares Outstanding | 45,420,677 | 35,526,281 |
Material Changes vs. Prior Period
- Revenue Generation: The company recognized $42,000 in revenue from a research services agreement, compared to zero in the prior year. Gross profit was zero as costs equaled revenue.
- Increased Operating Loss: Net loss increased by 27% to $2.6 million, driven primarily by a 53% increase in R&D expenses ($1.1M vs $0.7M) due to consulting fees for EB613 Phase 3 preparation and share-based compensation.
- Significant Capital Raise: Financing activities provided $13.3 million in net cash, a stark contrast to $30,000 in the prior year. This was driven by:
- $6.0 million net proceeds from an At-The-Market (ATM) offering.
- $8.0 million in proceeds from issuing shares to OPKO Health under a new collaboration agreement (held in restricted cash).
- Liquidity Position: Total cash and restricted cash more than doubled to $20.7 million. However, $8.0 million is restricted for the OPKO collaboration program.
Guidance, Outlook, and Risks
- Going Concern: Management states that current resources are sufficient to fund operations through the middle of Q3 2026. However, this excludes the capital required to initiate the Phase 3 program for EB613. The filing explicitly states these factors raise "substantial doubt" about the company's ability to continue as a going concern without additional financing.
- OPKO Collaboration: A new agreement with OPKO focuses on developing an oral OXM (GLP-1/Glucagon) tablet for obesity. Entera retains 40% of proceeds and bears 40% of costs, with an option to opt-out after Phase 1. The $8M proceeds are escrowed specifically for this program.
- Clinical Pipeline:
- EB613 (Osteoporosis): Preparing for Phase 3. Success depends on FDA qualification of the BMD endpoint via the SABRE project, expected in 2025.
- EB612 (Hypoparathyroidism): Testing new generations of N-Tab technology.
- Geopolitical Risk: The ongoing Israel-Hamas war and regional conflicts are noted as risks. Management currently assesses the impact on operations as immaterial, with core activities outside Israel unaffected.
Investor Verification Checklist
- Restricted Cash Usage: Verify the specific disbursement terms for the $8.0 million escrowed for the OPKO collaboration and the conditions under which remaining funds revert to Entera.
- Phase 3 Funding Gap: Confirm the estimated capital required to launch the EB613 Phase 3 trial, as current cash runway explicitly excludes this cost.
- SABRE Endpoint Qualification: Monitor FDA updates regarding the SABRE project's qualification of BMD as a surrogate endpoint, which is critical for the EB613 development strategy.
- Dilution Impact: Review the impact of the recent share issuances (ATM and OPKO deal) on existing shareholder ownership, noting the increase in shares outstanding from ~35.5M to ~45.4M in one quarter.
- Going Concern Status: Assess the likelihood of securing additional financing before Q3 2026 to fund the critical Phase 3 trial.